UCB SA (OTCMKTS:UCBJY) Short Interest Down 73.8% in June

UCB SA (OTCMKTS:UCBJY) was the recipient of a significant drop in short interest in June. As of June 30th, there was short interest totaling 5,769 shares, a drop of 73.8% from the June 15th total of 21,989 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 70,017 shares, the short-interest ratio is currently 0.1 days.

UCB Price Performance

UCBJY stock traded down $6.83 during trading on Friday, reaching $135.91. 23,360 shares of the stock were exchanged, compared to its average volume of 27,183. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.38 and a quick ratio of 1.04. The business has a 50 day moving average price of $144.02 and a 200-day moving average price of $147.99. UCB has a 1 year low of $98.24 and a 1 year high of $168.76.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on UCBJY. Zacks Research raised shares of UCB from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Barclays lowered shares of UCB from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 15th. Finally, Jefferies Financial Group upgraded UCB to a “moderate sell” rating in a report on Monday, June 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, UCB currently has a consensus rating of “Moderate Buy”.

UCB Company Profile

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.